| ¿µ¹® | breast cancer | ÇÑ±Û | À¯¹æ¾Ï |
|---|---|---|---|
| ¼³¸í | À¯¹æÀº Áö¹æÁ¶Á÷°ú º»·¡ÀÇ ¸ñÀûÀÎ Á£À» »ý»êÇÏ´Â »ùÁ¶Á÷, ±×¸®°í ÀÌ »ùÁ¶Á÷¿¡¼ »ý»êÇÑ Á£À» ¹Û¿¡±îÁö ³»º¸³»´Â °üÁ¶Á÷, ±×¸®°í ÀÌ »ùÁ¶Á÷°ú °üÁ¶Á÷ÀÇ ÁÖÀ§¸¦ µÑ·¯½Î°í ÀÖÀ¸¸é¼ À̰͵éÀÇ ¸ð¾çÀ» À¯ÁöÇØÁÖ´Â °£Áú·Î ÀÌ·ç¾îÁø´Ù. À¯¹æ¾ÏÀ̶õ »ùÁ¶Á÷°ú °üÁ¶Á÷¿¡¼ ±â¿øÇÏ´Â Á¾¾çÀ» ¸»ÇÑ´Ù. À¯¹æ¾ÏÀ» ¹ß»ý½Ãų ¼ö ÀÖ´Â À§ÇèÀÎÀÚ´Â ¿©·¯ °¡Áö°¡ ¹àÇôÁ® ÀÖ´Ù. ±×Áß¿¡¼ ´ëÇ¥ÀûÀÎ °ÍÀº ´ÙÀ½°ú °°´Ù. 1.À¯ÀüÀû ¿äÀΣ°¡Á· Áß¿¡¼ À¯¹æ¾Ï¿¡ °É¸° »ç¶÷ÀÌ ÀÖÀ¸¸é À¯¹æ¾ÏÀÇ ¹ß»ýÈ®·üÀÌ ¾ÆÁÖ ³ô¾ÆÁø´Ù. 2.¿¡½ºÆ®·Î°Õ¿¡ Àå±âÀûÀ¸·Î ¸¹ÀÌ Æø·ÎµÇ´Â °æ¿ì£¿¡½ºÆ®·Î°ÕÀº ¿©¼ºÈ£¸£¸óÀ¸·Î ¿©¼º¿¡¼ Á¤»óÀûÀ¸·Î »ý¸®ÀÇ Áֱ⿡ µû¶ó Áõ°¨À» µÇÇ®ÀÌÇÑ´Ù. ÀÌ ¿¡½ºÆ®·Î°ÕÀº À¯¹æÀÇ Á¥»ùÁ¶Á÷°ú °üÁ¶Á÷ÀÇ Áõ½Ä°ú ¼ºÀå¿¡ °ü°èÇÑ´Ù. ±×¸®°í ÀÌ ¿¡½ºÆ®·Î°Õ¿¡ ¸¹ÀÌ Æø·ÎµÇ´Â »ç¶÷Àº À¯¹æ¾ÏÀÇ È®·üÀÌ ³ô´Ù. ¿ÜºÎ¿¡¼ ¿¡½ºÆ®·Î°ÕÀÇ Á¦Á¦¸¦ Ä¡·á¸ñÀûÀ¸·Î Åõ¿©ÇÒ °æ¿ì¿¡ À¯¹æ¾ÏÀÇ ¹ß»ýÈ®·üÀº Á¤»óÀο¡¼ º¸´Ù ÇöÀúÇÏ°Ô ³ô¾ÆÁø´Ù. ±×¸®°í ¾ÆÀ̸¦ ³ºÁö ¾Ê°í Æò»ýÀ» »ç´Â ¿©ÀÚÀÇ °æ¿ì¿¡ ÀÓ½ÅÀ» ÇÏ°í ¾ÆÀ̸¦ ³ºÀº ¿©ÀÚ¿¡ ºñÇØ¼ ¿¡½ºÆ®·Î°Õ¿¡ ¸¹ÀÌ Æø·Î°¡ µÇ¹Ç·Î(ÀӽŽÿ¡´Â ºñÀӽŽú¸´Ù ¿¡½ºÆ®·Î°Õ¿¡ Àû°Ô Æø·Î°¡ µÈ´Ù)À¯¹æ¾ÏÀÇ È®·üÀÌ ³ô´Ù. 3.ȯ°æÀû ¿äÀΣÁö¹æÁú ¼·ÃëÀÇ Áõ°¡, ¼úÀÇ ¼·Ãë µîÀº À¯¹æ¾ÏÀÇ È®·üÀ» ³ôÀδÙ. À¯¹æ¾ÏÀÇ Áõ»óÀ¸·Î °¡Àå ¸¹Àº °ÍÀº ¾ÆÇÁÁö ¾ÊÀº À¯¹æÀÇ µ¢¾î¸®ÀÌ´Ù. ±×¸®°í À¯µÎ¿¡¼ ºÐºñ¹°ÀÌ ³ª¿À°Å³ª, À¯¹æÀÇ ÇǺκ¯È µîÀÌ À¯¹æ¾ÏÀÇ ÈçÇÑ Áõ»óÀÌ´Ù. Ä¡·á´Â À¯¹æÀÇ ÀýÁ¦¼úÀÌ °¡Àå È¿°úÀûÀÎ Ä¡·á¹ýÀ¸·Î µÇ¾îÀÖ´Ù. ±×¸®°í À̰Ϳ¡ ´õÇÏ¿© ¹æ»ç¼± Ä¡·á³ª Ç×¾ÏÁ¦¿ä¹ýµµ È¿°ú°¡ ÀÖ´Â °ÍÀ¸·Î µÇ¾îÀÖ´Ù. ¶Ç ¿¡½ºÆ®·Î°ÕÀÇ °úÀ×°ú °ü°è°¡ ÀÖ´Â Á¾¾çÀÏ °æ¿ì¿¡´Â ¿¡½ºÆ®·Î°ÕÀÇ È¿°ú¸¦ Â÷´ÜÇÏ´Â ¾à¹°µµ È¿°ú°¡ ÀÖ´Ù. |
||
| ¿µ¹® | metastasis | ÇÑ±Û | ÀüÀÌ |
|---|---|---|---|
| ¼³¸í | ´Ù¸¥ °÷À¸·Î ¿Å°Ü °£´Ù´Â ¶æÀ¸·Î ¾î¶² Á¾¾çÀÇ ¹ß»ý½Ã ±×°ÍÀÌ ¾Ç¼ºÀÎÁö ȤÀº ¾ç¼ºÀÎÁö ±¸º°ÇÏ´Â ¹æ¹ý Áß¿¡ °¡Àå Áß¿äÇÑ °ÍÀÌ ÀÌ "ÀüÀÌ"ÀÌ´Ù. ´Ù¸¥ °÷À¸·Î ÀüÀ̰¡ °¡´ÉÇϸé, ±×°ÍÀº ¾Ç¼ºÀ¸·Î »ý¸í¿¡ ÁöÀåÀ» ÁÙ À§ÇèÇÑ Á¾¾çÀÓÀ» ¶æÇϰí ÀüÀ̰¡ ¾øÀ¸¸é, ´ÜÁö ±× ±â°ü¿¡¸¸ ħÀÔÇÏ´Â ¾ç¼ºÀ» ¶æÇÑ´Ù. |
||
| ¿µ¹® | funnel breast | ÇÑ±Û | ¿À¸ñ°¡½¿, ´©µÎÈä |
|---|---|---|---|
| ¼³¸í | ¾Õ°¡½¿ÀÇ Á߾Ӻΰ¡ ±ò´ë±â ¸ð¾çÀ¸·Î ÇÔ¸ôµÇ¾î ÀÖ´Â °Í. ´ëºÎºÐ À¯Àü¼ºÀ¸·Î ½ÉÇÑ °æ¿ì¿¡´Â ½ÉÀåÀ̳ª ÇãÆÄ¿¡ Àå¾Ö¸¦ ÀÏÀ¸Å²´Ù. Àα¸ 300~400¸íÀÇ ½Å»ý¾Æ Áß 1¸íÀÌ ÀÌ Áúȯ¿¡ °É¸± ¼ö ÀÖ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù. º¸Åë ÀÌ Áõ»óÀ» °®°í ÀÖ´Â »ç¶÷Àº ¸¶¸¥Ã¼ÇüÀ̰í ôÃßÈĸ¸ µî ÀÚ¼¼ÀÇ ÀÌ»óÀ» µ¿¹ÝÇÏ´Â °æ¿ì°¡ ¸¹´Ù. º¸Åë ½Å»ý¾Æ±â, ¿µ¾Æ±â µî ¾î·Á¼ºÎÅÍ ¾Ë°Ô µÇ¸ç, ±âÇüÀûÀÎ ¸ð½À ¶§¹®¿¡ Çб³»ýȰÀ̳ª »çȸ»ýȰÀ» ÇÒ ¶§ ÁöÀåÀ» ¹ÞÀ» ¼öµµ ÀÖ´Ù. ³²ÀÚ¿¡°Ô ¸¹ÀÌ ¹ß»ýÇϰí, »ó±âµµÆó»ö-±â°üÁö¿¬ÈÁõ°ú °ü·ÃµÇ¾î »ý±æ ¼öµµ ÀÖ´Ù. º¸ÅëÀÇ °æ¿ì Áõ»óÀÌ ¾øÁö¸¸, ½ÉÇÑ °æ¿ì ½ÉÆó±â´ÉÀÇ Àå¾Ö·Î ÀÎÇØ ¿îµ¿ÇÒ ¶§ ¼ûÀÌ Â÷°í, ¹Ýº¹µÇ´Â °¨±âÁõ»óÀÌ ÀÖÀ» ¼ö ÀÖ´Ù. ½Â¸ðÆÇ Å»Ãâ, Á¶±âÈïºÐÁõÈıºÀÌ ³ªÅ¸³ª´Â °æ¿ìµµ ÀÖ´Ù. |
||
| ¿µ¹® | fibrocystic disease of breast | ÇÑ±Û | À¯¹æ ¼¶À¯³¶º´ |
|---|---|---|---|
| ¼³¸í | Á¥À» »ý»êÇÏ´Â Á¥»ù³»¿¡ ¿ÏµÎÄá ¶Ç´Â Å«Äá Å©±âÀÇ °áÀýÀÌ ¹ß»ýÇÏ´Â Áõ¼¼¸¦ Ư¡À¸·Î ÇÏ´Â º´. 30~50´ëÀÇ ºÎÀο¡°Ô ÈçÈ÷ ¹ß»ýÇϸç, ±× ´ëºÎºÐÀº ¾çÂÊ À¯¹æ¿¡ µ¿½Ã¿¡ ¹ß»ýÇÑ´Ù. ÀÌ·¯ÇÑ °áÀýÀº µÎ ¼Õ°¡¶ô »çÀÌ¿¡ ³¢¿ö ÃËÁøÇÒ ¶§´Â ºÐ¸íÇÏÁö¸¸, È亮À» ¼Õ¹Ù´ÚÀ¸·Î ´©¸£¸é ¸í·áÇÏÁö ¾ÊÀ» Á¤µµ·Î ºÎµå·¯¿î °ÍÀÌ ¸¹´Ù. ±× ¹ß»ý ¿øÀο¡´Â ¿©·¯ °¡Áö ¼³ÀÌ ¸¹Àºµ¥, Á¥»ùÁ¶Á÷¿¡ ´ëÇÑ ¸¸¼ºÀûÀÎ ÀÚ±ØÀÌ ÁÖ¿øÀÎÀ̶ó »ý°¢µÇ°í ÀÖÀ¸¸ç, ±ØÈ÷ ¼¼È÷ ÁøÇàÇÏ´Â °æ°ú¸¦ ¹â´Â´Ù. Áø´ÜÀº ÃËÁø, ÃÊÀ½ÆÄÁø´Ü µîÀ¸·Î Çϸç, ¾Ï°ú °¨º°ÀÌ °ï¶õÇÒ ¶§´Â Á¶Á÷ÀÇ ÀϺθ¦ äÃëÇÏ¿© °Ë»çÇÏ´Â »ý°ËÀÌ ÀÌ¿ëµÇ±âµµ ÇÑ´Ù. |
||
| ¿µ¹® | ovarian cancer | ÇÑ±Û | ³¼Ò¾Ï |
|---|---|---|---|
| ¼³¸í | ¿©¼ºÀÇ ³¼Ò¿¡ ¹ß»ýÇÏ´Â ¾Ï. ºÎÀΰúÁ¾¾çÀ¸·Î¼ 50¼¼ ÀÌ»ó ¿©¼º¾Ç¼ºÁ¾¾çÀÇ ¾à 18%¸¦ Â÷ÁöÇÑ´Ù. Á¾¾çÀº ´ë°³ º¹ºÎ ±í¼÷È÷ À§Ä¡ÇϹǷΠÁ¾¾çÀÌ ¸¹ÀÌ ÁøÇàµÈ »óÅ¿¡¼ ¹ß°ßµÇ´Â ¼ö°¡ ¸¹À¸¸ç, ¶ÇÇÑ Á¾¾çÀÇ Ãʱ⿡´Â Áõ»óÀÌ °ÅÀÇ ¾ø´Â °æ¿ì°¡ ¸¹¾Æ ´õ¿í Á¶±â¹ß°ßÀÌ ¾î·Æ´Ù. ¾ÆÁÖ ´Ù¾çÇÑ Á¾·ùÀÇ ¾ÏÀÌ ¹ß»ýÇϸç, ¿¹Èĵµ °¢±â ±× Á¾¾çÀÇ Á¾·ù¿¡ µû¶ó ´Ù¸£´Ù. ´ëÇ¥ÀûÀÎ ¾ÏÀ¸·Î À强³¶»ù¾ÏÁ¾(serous cystadenocarcinoma), Á¡¾×³¶»ù¾ÏÁ¾(mucinous cystadenocarcinoma), Á¾ÀÚ¼¼Æ÷Á¾(germinoma µîÀÌ ÀÖ´Ù. Ä¡·á´Â ¼ö¼úÀû Ä¡·á°¡ ¼±ÇàµÇ¾î¾ß ÇÏÁö¸¸, ¸¹ÀÌ ÁøÇàµÇ¾î ÀÌ¹Ì ´Ù¸¥ Á¶Á÷À¸·Î ÀüÀ̰¡ ÀÌ·ç¾îÁø »óÅ¿¡¼´Â ÈÇпä¹ýÀÌ ¼±ÅÃÀûÀ¸·Î »ç¿ëµÈ´Ù. |
||
| CEA | Carcino-Embryonic Antigen [HP 1825-6] ; Oncofetal Antigens ; Glycopro... |
|---|---|
| GTN | - Stages of GTN(FIGO, WHO) 1. Stage O; Molar Pregnancy(H-Mole... |
| AFP | Alpha(¥á) Feto-Protein [HP 1826, 1858, 1859, 2265] ; Oncofetal Antigens &nbs... |
| MBC | male breast cancer; maximal bladder capacity; maximal breathing capacity; metastatic breast cancer; ... |
| TNM | primary tumor, regional nodes, metastasis [tumor staging]; thyroid node metastases; tumor node metas... |
| MFS | Metastasis-free survival |
|---|---|
| TNM | Tumor Node Metastasis |
| n 0 | node metastasis |
| BC | Breast Cancer |
| BCDDP | Breast Cancer Detection Demonstration Project |
| BRCA1 breast cancer susceptibility gene | This mutated (changed) version of the BRCA1 gene makes a person susceptible to developing breast cancer. (12 Dec 1998) |
|---|---|
| breast cancer | <oncology> The uncontrolled growth of malignant breast tissue. Breast cancer is currently the most common cancer in women and the leading cause of cancer-related death in the 15-54 age group. Strong risk factors include a prior history for breast cancer or a positive family history for breast cancer. Early detection is possible through the use of monthly breast self-examination, annual clinical exams and mammography. WWW: cancerNET document for patients WWW: cancerNET document for clinicians (05 Jan 1998) |
| breast cancer susceptibility genes | Inherited factors that predispose to breast cancer. Put otherwise, these genes make one more susceptible to the disease and so increase the risk of developing breast cancer. Two of these genes, BRCA1 and BRCA2, have been identified (and prominently publicised). Several other genes (those for the Li-Fraumeni syndrome, Cowden disease, Muir-Torre syndrome, and ataxia-telangiectasia) are also known to predispose to breast cancer. However, since all of these known breast cancer susceptibility genes together do not account for more than a minor fraction (1/5th at most) of breast cancer that clusters in families, it is clear that more breast cancer genes remain to be discovered. (12 Dec 1998) |
| cancer, breast | Cancer of the tissue containing or involving the milk glands (mammary tissue). Breast cancer is diagnosed with self- and physician- examination of the breasts, mammography, ultrasound testing, and biopsy. There are many types of breast cancer that differ in their capability of spreading to other body tissues (metastasis). Treatment of breast cancer depends on the type and location of the breast cancer, as well as the age and health of the patient. The American Cancer Society recommends that a woman should have a baseline mammogram between the ages of 35 and 40 years. Between 40 and 50 years of age mammograms are recommended every other year. After age 50 years, yearly mammograms are recommended. (12 Dec 1998) |
| cancer, breast, familial | A number of factors have been identified that increase the risk of breast cancer. One of the strongest of these risk factors is the history of breast cancer in a relative. About 15-20% of women with breast cancer have such a family history of the disease, clearly reflecting the participation of inherited (genetic) components in the development of some breast cancers. Dominant breast cancer suceptibility genes, including BRCA1 and BRCA2, appear responsible for about 5% of all breast cancer. (12 Dec 1998) |
| cancer, breast, susceptibility genes | Inherited factors that predispose to breast cancer. Put otherwise, these genes make one more susceptible to the disease and so increase the risk of developing breast cancer. Two of these genes, BRCA1 and BRCA2, have been identified (and prominently publicised). Several other genes (those for the Li-Fraumeni syndrome, Cowden disease, Muir-Torre syndrome, and ataxia-telangiectasia) are also known to predispose to breast cancer. However, since all of these known breast cancer susceptibility genes together do not account for more than a minor fraction (1/5th at most) of breast cancer that clusters in families, it is clear that more breast cancer genes remain to be discovered. (12 Dec 1998) |
| genes, breast cancer susceptibility | Inherited factors that predispose to breast cancer. Put otherwise, these genes make one more susceptible to the disease and so increase the risk of developing breast cancer. Two of these genes, BRCA1 and BRCA2, have been identified (and prominently publicised). Several other genes (those for the Li-Fraumeni syndrome, Cowden disease, Muir-Torre syndrome, and ataxia-telangiectasia) are also known to predispose to breast cancer. Howeverm, since all of these known breast cancer susceptibility genes together do not account for more than a minor fraction (1/5th at most) of breast cancer that clusters in families, it is clear that more breast cancer genes remain to be discovered. See related entries to: BRCA1; BRCA2; Breast cancer, familial. (12 Dec 1998) |
| metastatic breast cancer | Breast cancer that has spread to other parts of the body. (16 Dec 1997) |
| early stage breast cancer | <oncology> Cancer is confined to the breast and has not spread to other sites in the body. (16 Dec 1997) |
| familial breast cancer | <oncology> A number of factors have been identified that increase the risk of breast cancer. One of the strongest of these risk factors is the history of breast cancer in a relative. About15-20% of women with breast cancer have such a family history of the disease, clearly reflecting the participation of inherited (genetic) components in the development of some breast cancers. Dominant breast cancer suceptibility genes, including BRCA1 and BRCA2, appear responsible for about 5% of all breast cancer. See related entries to: Breast cancer susceptibility genes; BRCA1; BRCA2. There are 2 genes; BRCA1 and BRCA2 which are susceptibility genes for breast cancer. They are inherited factors that predispose to breast cancer. Put otherwise, these genes make one more susceptible to the disease and so increase the risk of developing breast cancer. Two of these genes, BRCA1 and BRCA2, have been identified (and prominently publicised). Several other genes (those for the li-fraumeni syndrome, cowden disease, muir-torre syndrome, and ataxia-telangiectasia) are also known to predispose to breast cancer. However, since all of these known breast cancer susceptibility genes together do not account for more than a minor fraction (1/5th at most) of breast cancer that clusters in families, it is clear that more breast cancer genes remain to be discovered. (12 Dec 1998) |
| biochemical metastasis | The transportation and induction of abnormal immunochemical specificities in apparently normal organs. (05 Mar 2000) |
| calcareous metastasis | The deposit of calcareous material in remote tissues in the event of extensive resorption of osseous tissue in caries, malignant neoplasms, and so on. (05 Mar 2000) |
| metastasis | 1. <cell biology, oncology> The transfer of disease from one organ or part to another not directly connected with it. It may be due either to the transfer of pathogenic microorganisms (for example, tubercle bacilli) or to transfer of cells, as in malignant tumours. The capacity to metastasize is a characteristic of all malignant tumours. 2. Pleural: metastases. A growth of pathogenic microorganisms or of abnormal cells distant from the site primarily involved by the morbid process. Origin: Gr. Stasis = stand, stoppage (12 Nov 1997) |
| haematogenous metastasis | See: metastasis. (05 Mar 2000) |
| satellite metastasis | Metastasis within the immediate vicinity of a primary malignant neoplasm; e.g., skin adjacent to a melanoma. (05 Mar 2000) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|